A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer

European Urology

Volumn 57, Issue 1, 2010, Pages 79-85

  Roobol, Monique J ^a   Steyerberg, Ewout W ^a   Kranse, Ries ^a   Wolters, Tineke ^a   van den Bergh, Roderick C N ^a   Bangma, Chris H ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biopsy; DRE; Indolent prostate cancer; Multivariate analysis; Nomogram; Prostate cancer; PSA; Risk stratification; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL DECISION MAKING; DIGITAL RECTAL EXAMINATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NOMOGRAM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY;

ALGORITHMS; BIOPSY; DIGITAL RECTAL EXAMINATION; HEALTH STATUS INDICATORS; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; NETHERLANDS; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNNECESSARY PROCEDURES;

EID: 70449525320     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.08.025     Document Type: Article

References (30)

1. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. New Engl J Med 360 (2009) 1320-1328
2. Roobol M.J., Kerkhof M., Schröder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for non-attendance and contamination in the European Randomised study of Screening for Prostate Cancer (ERSPC). Eur Urol 56 (2009) 584-591
3. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
4. Catalona W.J., Loeb S., and Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 144 (2006) 441-443
5. Welch H.G., Schwartz L.M., and Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 97 (2005) 1132-1137
6. Schröder F.H., and Roobol M. Comment on prostate-specific antigen levels in the United States: implications of various definitions for abnormal. Eur Urol 49 (2006) 412-413
7. Ankerst D.P., and Thompson I.M. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl 78 (2006) 125-129
8. Ankerst D.P., and Thompson I.M. Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool. Arch Ital Urol Androl 78 (2006) 143-146
9. Garzotto M., Hudson R.G., Peters L., et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤10 ng/ml. Cancer 98 (2003) 1417-1422
10. Karakiewicz P.I., Benayoun S., Kattan M.W., et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 173 (2005) 1930-1934
11. Chun F.K.-H., Graefen M., Briganti A., et al. Initial biopsy outcome prediction-head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 51 (2007) 1236-1243 discussion 1241-3
12. Virtanen A., Gomari M., Kranse R., and Stenman U.H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45 (1999) 987-994
13. Kranse R., Beemsterboer P., Rietbergen J., Habbema D., Hugosson J., and Schroder F.H. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 39 (1999) 316-322
14. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
15. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
16. Yao S.L., and Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 94 (2002) 958-960
17. Zappa M., Ciatto S., Bonardi R., and Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 12 (1998) 1297-1300
18. Kranse R., Roobol M.J., and Schröder F.H. A graphical device to represent the outcomes of a logistic regression analysis, an illustration of its possible use in prostate cancer screening and prostate cancer treatment counseling. Prostate 68 (2008) 1674-1680
19. Steyerberg E.W., Roobol M.J., Kattan M.W., van der Kwast T.H., de Koning H.J., and Schröder F.H. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177 (2007) 107-112
20. ®. ERSPC Rotterdam, Helsinki and Tampere. Eur Urol Suppl 8 (2009) 192
21. Dong F., Kattan M.W., Steyerberg E.W., et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 180 (2008) 150-154 discussion 154
22. Risk of biopsy-detectable prostate cancer. University of Texas Health Science Center Web site. http://www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp. Accessed July 13, 2009.
23. van den Bergh R.C.N., Roobol M.J., Wolters T., van Leeuwen P.J., and Schröder F.H. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 102 (2008) 1068-1073
24. Bangma C.H., Roemeling S., and Schröder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25 (2007) 3-9
25. Pashayan N., Powles J., Brown C., and Duffy S.W. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia [published correction appears in Br J Cancer 2006;95:660]. Br J Cancer 95 (2006) 401-405
26. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
27. Welch H.G., Fisher E.S., Gottlieb D.J., and Barry M.J. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 99 (2007) 1395-1400
28. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
29. Capitanio U., Karakiewicz P.I., Valiquette L., et al. Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer. Urology 73 (2009) 1087-1091
30. Serkin FB, Soderdahl DW, Cullen J, Chen Y, Hernandez J. Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7. Urol Oncol. In press. DOI:10.1016/j.urolonc.2008.09.030.